Clinical Trials for Non-Small Cell Lung Cancer

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the safety and efficacy of combining pembrolizumab, a PD-1 inhibitor, with the experimental ornithine decarboxylase inhibitor DFMO in patients aged 18 or older with Stage IV NSCLC and STK11 mutations, focusing on those who are treatment-naïve or have progressed after previous therapies.

ClinicalTrials.gov ID: NCT06219174

Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adult patients with advanced non-squamous NSCLC (Stage IV or recurrent) who progressed after maintenance therapy with pemetrexed and/or pembrolizumab, excluding those with certain mutations or untreated brain metastases. The regimen includes carboplatin and paclitaxel, standard chemotherapeutics, combined with ramucirumab, a monoclonal antibody targeting VEGFR-2 to inhibit angiogenesis.

ClinicalTrials.gov ID: NCT04332367

An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates the combination of Trans-Arterial Tirapazamine Embolization (TATE) and Pembrolizumab in patients with metastatic colorectal cancer (mCRC) and non-small cell lung cancer (NSCLC) who have liver metastases and have progressed after prior therapies. TATE delivers the hypoxia-activated prodrug Tirapazamine to liver tumors, while Pembrolizumab, an immune checkpoint inhibitor, blocks the PD-1 pathway to enhance anti-tumor immunity.

ClinicalTrials.gov ID: NCT04701476

Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This clinical trial investigates the use of CD40L-augmented tumor-infiltrating lymphocytes (TIL) combined with nivolumab for adults with stage IV or recurrent NSCLC harboring EGFR, ALK, ROS1, or HER2 mutations who have progressed following prior therapy. CD40L TIL are engineered to enhance immune response against cancer, while nivolumab blocks the PD-1 pathway, aiming to improve treatment outcomes in this patient population.

ClinicalTrials.gov ID: NCT05681780

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial investigates the efficacy of combining osimertinib, an EGFR-tyrosine kinase inhibitor, with bevacizumab, a VEGF inhibitor, versus osimertinib alone in treatment-naïve patients with advanced EGFR-mutant NSCLC. Eligible patients have EGFR-mutated NSCLC (stages IIIB-IV) with specific activating mutations.

ClinicalTrials.gov ID: NCT04181060

A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial targets patients with immunotherapy and chemotherapy naïve metastatic NSCLC with high PD-L1 TPS, EGFR and ALK mutation-negative disease, and detectable ctDNA, and investigates pembrolizumab alone or in combination with platinum-based chemotherapy.

ClinicalTrials.gov ID: NCT04093167

TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates the efficacy of adding atezolizumab, a PD-L1 inhibitor, to a regimen of carboplatin, pemetrexed, and bevacizumab in treating stage IV non-squamous NSCLC patients who harbor EGFR mutations or are never smokers with wild-type tumors lacking ALK or ROS1 rearrangements. The study compares outcomes between a treatment arm including the investigational drug atezolizumab and a standard treatment arm without it.

ClinicalTrials.gov ID: NCT03786692

Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves immunotherapy-naive patients with stage IV non-small cell lung cancer receiving treatment with nivolumab and ipilimumab, which are immune checkpoint inhibitors targeting PD-1 and CTLA-4, respectively; one group also receives local consolidation therapy to assess its impact on overall survival.

ClinicalTrials.gov ID: NCT03391869

A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial enrolls patients with advanced or recurrent non-small cell lung cancer having EGFR mutations and MET amplification, who progressed after osimertinib, to assess the efficacy of capmatinib (a MET inhibitor) and osimertinib with or without ramucirumab (an anti-angiogenic antibody).

ClinicalTrials.gov ID: NCT05642572

An Open-Label Phase I/II Study to Evaluate the Safety and prelimiBasnary Efficacy of Amivantamab and Tepotinib Combination in MET-altered Non-small Cell Lung Cancer (NSCLC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced MET-altered non-small cell lung cancer (NSCLC), specifically MET exon 14 skipping alterations or MET gene amplification, and evaluates the safety and efficacy of the combination treatment of amivantamab, a bispecific antibody targeting EGFR and c-MET, and tepotinib, an oral MET inhibitor.

ClinicalTrials.gov ID: NCT06083857